A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
- Status
- COMPLETED
- Phase
- PHASE1
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
- Status
- COMPLETED
- Phase
- PHASE2
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
- Status
- COMPLETED
- Phase
- PHASE4
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
- Status
- WITHDRAWN
- Phase
- PHASE1
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE2